Assets
+ UCB
History
2022: Purchase of epilepsy drugmaker Zogenix for $1.9 billion
On January 19, 2022, the Belgian pharmaceutical UCB announced the conclusion of an agreement to acquire Zogenix for $1.9 billion. The boards of directors of both companies approved the deal, it is planned to close in the second quarter of 2022. More details here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |